Advancement of AbbVie Inc. and OSE Immunotherapeutics strategic partnership to develop ABBV-230: in April 2024, the Hart-Scott-Rodino waiting period expired enabling teams to commence work around the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback